European Investor
01 May 2026, 14:21
Moderna Shares Fall 3.4% as Earnings Highlight Losses Despite Pipeline Progress
Shares of Moderna, Inc. declined 3.44% to $44.36 on today, as investors reacted to the company’s first-quarter 2026 earnings, which revealed significant losses driven by one-time charges despite improving revenue trends and pipeline developments.
The biotech firm reported quarterly revenue of $389 million, a sharp increase compared to the prior year, largely supported by higher COVID-19 vaccine sales in international markets. Approximately 80% of total revenue came from outside the United States, reflecting the company’s growing global footprint.
However, profitability remained under pressure. Moderna posted a GAAP net loss of $1.3 billion, with a loss per share of $3.40. A major factor behind the loss was a $0.9 billion non-recurring litigation settlement charge, which significantly weighed on earnings during the quarter.
Despite the headline loss, underlying cost discipline showed improvement. Research and development expenses declined 24% year-over-year, while selling, general and administrative expenses fell 18%, indicating ongoing efforts to streamline operations following the pandemic-driven peak period.
On the strategic front, Moderna continued to advance its pipeline. The company secured key regulatory approvals in Europe, including for its flu and COVID combination vaccine, and initiated a Phase 3 trial for a lung cancer treatment. These developments underscore its transition toward a broader portfolio beyond COVID vaccines.
CEO Stéphane Bancel emphasized confidence in returning to revenue growth in 2026, supported by upcoming product launches and continued clinical progress across multiple therapeutic areas.
Looking ahead, Moderna reiterated its expectation of up to 10% revenue growth for full-year 2026, alongside plans to reduce operating expenses excluding the one-time litigation impact. The company also projected year-end cash and investments between $4.5 billion and $5.0 billion, maintaining a solid liquidity position.
Overall, while revenue growth and pipeline momentum provided some positive signals, the substantial quarterly loss and ongoing transition period appear to have weighed on investor sentiment, pushing the stock lower following the earnings release.
Shares of Moderna, Inc. declined 3.44% to $44.36 on today, as investors reacted to the company’s first-quarter 2026 earnings, which revealed significant losses driven by one-time charges despite improving revenue trends and pipeline developments.
The biotech firm reported quarterly revenue of $389 million, a sharp increase compared to the prior year, largely supported by higher COVID-19 vaccine sales in international markets. Approximately 80% of total revenue came from outside the United States, reflecting the company’s growing global footprint.
However, profitability remained under pressure. Moderna posted a GAAP net loss of $1.3 billion, with a loss per share of $3.40. A major factor behind the loss was a $0.9 billion non-recurring litigation settlement charge, which significantly weighed on earnings during the quarter.
Despite the headline loss, underlying cost discipline showed improvement. Research and development expenses declined 24% year-over-year, while selling, general and administrative expenses fell 18%, indicating ongoing efforts to streamline operations following the pandemic-driven peak period.
On the strategic front, Moderna continued to advance its pipeline. The company secured key regulatory approvals in Europe, including for its flu and COVID combination vaccine, and initiated a Phase 3 trial for a lung cancer treatment. These developments underscore its transition toward a broader portfolio beyond COVID vaccines.
CEO Stéphane Bancel emphasized confidence in returning to revenue growth in 2026, supported by upcoming product launches and continued clinical progress across multiple therapeutic areas.
Looking ahead, Moderna reiterated its expectation of up to 10% revenue growth for full-year 2026, alongside plans to reduce operating expenses excluding the one-time litigation impact. The company also projected year-end cash and investments between $4.5 billion and $5.0 billion, maintaining a solid liquidity position.
Overall, while revenue growth and pipeline momentum provided some positive signals, the substantial quarterly loss and ongoing transition period appear to have weighed on investor sentiment, pushing the stock lower following the earnings release.
